Related references
Note: Only part of the references are listed.Antimicrobial categories in describing multidrug resistance, extensive drug resistance and pan-drug resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: a systematic review
Banafsheh Douzandeh-Mobarrez et al.
REVIEWS IN MEDICAL MICROBIOLOGY (2021)
Public Awareness and Practices towards Self-Medication with Antibiotics among the Malaysian Population. A Development of Questionnaire and Pilot-Testing
Adeel Aslam et al.
ANTIBIOTICS-BASEL (2020)
The Concept of an Ideal Antibiotic: Implications for Drug Design
Mario Gajdacs
MOLECULES (2019)
Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
Tianshui Niu et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2019)
OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains
Yunxing Yang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa
Chih-Cheng Lai et al.
INFECTION AND DRUG RESISTANCE (2019)
Resistance Levels and Epidemiology of Non-Fermenting Gram-Negative Bacteria in Urinary Tract Infections of Inpatients and Outpatients (RENFUTI): A 10-Year Epidemiological Snapshot
Mario Gajdacs et al.
ANTIBIOTICS-BASEL (2019)
Epidemiological Trends and Resistance Associated with Stenotrophomonas maltophilia Bacteremia: A 10-Year Retrospective Cohort Study in a Tertiary-Care Hospital in Hungary
Mario Gajdacs et al.
DISEASES (2019)
Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis
Kirati Kengkla et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae
Dhruvitkumar S. Sutaria et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
A Case-Control Study: Clinical Characteristics of Nosocomial Bloodstream Infections Versus Non-bloodstream Infections of Acinetobacter spp.
Su Xu et al.
CLINICAL INFECTIOUS DISEASES (2018)
Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms
Chih-Cheng Lai et al.
INFECTION AND DRUG RESISTANCE (2018)
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
Darren Wong et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Thomas F. Durand-Reville et al.
NATURE MICROBIOLOGY (2017)
Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam
Adam B. Shapiro
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014)
M. A. Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2017)
Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture
Yung-Chih Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
William F. Penwell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Clonal dissemination of extensively drug-resistant Acinetobacter baumannii producing an OXA-23 beta-lactamase at a teaching hospital in Shanghai, China
Ying Li et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2015)
Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii
Shu-Chen Kuo et al.
FRONTIERS IN MICROBIOLOGY (2015)
In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii
Jingshu Ji et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii
Lenka Krizova et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Early Insights into the Interactions of Different β-Lactam Antibiotics and β-Lactamase Inhibitors against Soluble Forms of Acinetobacter baumannii PBP1a and Acinetobacter sp PBP3
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae
Caroline Dallenne et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia
Alex P. Betrosian et al.
JOURNAL OF INFECTION (2008)
Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia:: Four case reports and an in vitro combination synergy study
Nan-Yao Lee et al.
PHARMACOTHERAPY (2007)
In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains
PG Higgins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii
JY Choi et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
In vitro activities of β-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria
FD Wang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2004)
Share Paper
